| __timestamp | Takeda Pharmaceutical Company Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 13774000 |
| Thursday, January 1, 2015 | 650773000000 | 22479000 |
| Friday, January 1, 2016 | 619061000000 | 27388000 |
| Sunday, January 1, 2017 | 628106000000 | 35610000 |
| Monday, January 1, 2018 | 717599000000 | 49007000 |
| Tuesday, January 1, 2019 | 964737000000 | 61139000 |
| Wednesday, January 1, 2020 | 875663000000 | 68836000 |
| Friday, January 1, 2021 | 886361000000 | 97592000 |
| Saturday, January 1, 2022 | 997309000000 | 106903000 |
| Sunday, January 1, 2023 | 1053819000000 | 120998000 |
| Monday, January 1, 2024 | 1053819000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a leader in the global market, has shown a consistent increase in its Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Takeda's SG&A expenses surged by approximately 72%, reflecting its aggressive expansion and strategic investments.
In contrast, Vericel Corporation, a smaller player, has also seen a significant rise in its SG&A expenses, growing nearly ninefold from 2014 to 2023. This growth underscores Vericel's commitment to scaling its operations and enhancing its market presence.
While Takeda's expenses dwarf those of Vericel, the upward trend in both companies highlights a shared focus on growth and market penetration. Notably, data for 2024 is incomplete, suggesting ongoing developments in their financial strategies.
Amgen Inc. or Takeda Pharmaceutical Company Limited: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Rhythm Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Agios Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited or Dynavax Technologies Corporation: Who Manages SG&A Costs Better?
BeiGene, Ltd. vs Vericel Corporation: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Vericel Corporation
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Vericel Corporation and ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.